Daily non-political popular news in brief.
Drug boosts platelets in hepatitis C patients
11-28-2007 · EurekAlert!It's not a cure, but this may be some of the best news patients infected with the hepatitis C virus have heard in a long time: A new drug, eltrombopag, appears to be effective in boosting low platelet counts, one of the major reasons why patients can't endure antiviral treatments. Other drugs that can restore normal platelet functions are infusions or injections; eltrombopag is a pill taken just once a day.
Read more »
Keywords: drug, boosts, platelets, hepatitis, patients, boost, platelet, hepatiti, patient
« Previous | Next »
Similar news on "Drug boosts platelets in hepatitis C patients":
- Eltrombopag effective for hepatitis C patients with low blood-platelet counts
12-28-2007 · EurekAlert!
For patients with hepatitis C, having a low blood platelet count is a frequent complication associated with advanced disease. This problem is compounded by the fact that standard antiviral treatment for the disease can further reduce platelet numbers to dangerously low levels, effectively denying these patients the treatment they urgently need. Now, research published in the New England Journal of Medicine finds that a new drug, eltrombopag, appears to significantly boost platelet counts, opening the door to effective treatment.
Similar news · Read more »
- Hepatitis B patients' understanding of infection and treatment deficient
05-24-2007 · EurekAlert!
Many patients with chronic hepatitis B are deficient in their understanding of the lifelong disease and often do not comply with the drug regimens necessary to control it, according to a new UCLA survey that suggests improved patient involvement in disease management decisions could be the key to fixing this problem.
Similar news · Read more »
- Hepatitis B drug can compromise HIV treatment
06-20-2007 · EurekAlert!
Treating hepatitis B patients with the drug entecavir can cause those who are also infected with HIV to become resistant to two of the most important drugs in the anti-HIV arsenal. In findings published in the New England Journal of Medicine, researchers reported that a patient infected with both hepatitis B and HIV who was treated with entecavir developed a mutant strain of HIV that is resistant to the antiviral drugs lamivudine and emtricitabine.
Similar news · Read more »
- New drug helps hepatitis C patients start antiviral therapy
10-30-2006 · EurekAlert!
A new drug that stimulates the production of blood platelets can enable patients infected with hepatitis C virus to take other antiviral medications they previously could not take to fight the disease, according to the results of a clinical trial led by a Duke University Medical Center researcher.
Similar news · Read more »
- Who will recover spontaneously from hepatitis C virus infection
08-29-2007 · EurekAlert!
An eight-year study led by Dr. Sabine Mihm from from Georg-August-Universitдt has investigated 67 spontaneously recovered patients and found that co-infection by hepatitis B virus is associated with a higher possibility of self recovery. In addition, patients who self recovered usually have lower levels of HCV antibody. But on the other hand, the researchers also found that active iv drug users are less likely to self recover.
Similar news · Read more »
- Lifetime trauma may speed progression of HIV, early death
11-01-2007 · EurekAlert!
Even though effective drug cocktails have improved the outlook for many patients with HIV, disease progression, including the time from AIDS onset to death, varies widely from patient to patient. Now, a study led by the University of North Carolina at Chapel Hill School of Medicine provides new evidence that psychological factors play a role in disease progression.
Similar news · Read more »
- Eltrombopag studied in Idiopathic Thrombocytopenic Purpura
11-28-2007 · EurekAlert!
There are estimated to be between 50,000-100,000 individuals in the US diagnosed with chronic Immune Thrombocytopenic Purpura, an autoimmune disease that dramatically reduces the number of platelets in their blood -- causing bruises, nosebleeds and, sometimes, life-threatening brain hemorrhages. Now, the results of an international multicenter clinical research study led by NewYork-Presbyterian Hospital/Weill Cornell Medical Center demonstrate that an investigational oral platelet growth factor called eltrombopag successfully increased platelet counts and decreased bleeding in patients with the condition.
Similar news · Read more »
- Israeli scientists identify: Genes that affect responses of multiple sclerosis patients to copaxone
10-10-2007 · EurekAlert!
Getting the drug dosage correct can be a tricky exercise in trial and error in a disease like multiple sclerosis. Scientists from the Weizmann Institute and the Technion have identified two genes that affect a patient's response to the drug Copaxone, a finding which may help take the some of the guesswork out of treatment.
Similar news · Read more »
- Mouse Tests Predict Drug Response In Relapsing Pancreatic Cancer Patients
10-12-2006 · ScienceDaily
By slicing up bits of patient tumors and grafting them into mice, Johns Hopkins Kimmel Cancer Center specialists have figured out how to accurately 'test drive' chemotherapy drugs to learn in advance which drug treatments offer each individual pancreatic cancer patient the best therapeutic journey.
Similar news · Read more »
- Drug based on MGH discovery may significantly improve treatment of dangerous blood disorder
01-31-2008 · EurekAlert!
Two clinical trials of the novel drug romiplostim show that it significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura, a hematologic disorder that can cause uncontrolled bleeding. An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a Massachusetts General Hospital investigator, in the Feb. 2 issue of the Lancet.
Similar news · Read more »
